University of Wollongong

Research Online
Faculty of Social Sciences - Papers

Faculty of Arts, Social Sciences & Humanities

2010

Future HIV vaccine acceptability among young adults in South Africa
Jennifer Sayles
University of California

Catherine L. Mac Phail
University of Wollongong, cmacphai@uow.edu.au

Peter Newman
University of Toronto

William Cunningham
University of California

Follow this and additional works at: https://ro.uow.edu.au/sspapers
Part of the Education Commons, and the Social and Behavioral Sciences Commons

Recommended Citation
Sayles, Jennifer; Mac Phail, Catherine L.; Newman, Peter; and Cunningham, William, "Future HIV vaccine
acceptability among young adults in South Africa" (2010). Faculty of Social Sciences - Papers. 2822.
https://ro.uow.edu.au/sspapers/2822

Research Online is the open access institutional repository for the University of Wollongong. For further information
contact the UOW Library: research-pubs@uow.edu.au

Future HIV vaccine acceptability among young adults in South Africa
Abstract
Developing and disseminating a preventive HIV vaccine is a primary scientific and public health objective.
However, little is known about HIV vaccine acceptability in the high-prevalence setting of South Africawhere young adults are likely to be targeted in early dissemination efforts. This study reports on six focus
groups (n = 42) conducted in 2007 with South Africans aged 18 to 24 years. A deductive framework
approach is used to identify key motivators and barriers to future HIV vaccine uptake. Participants identify
HIV testing, HIV stigma, mistrust of the health care system, and concerns about sexual disinhibition as
barriers to vaccine uptake. For women, family members and friends are strong motivators for vaccine
uptake, whereas men are more likely to see vaccines as an opportunity to stop using HIV prevention
strategies such as condoms and partner reduction. Implications of these findings for developing HIV
vaccine dissemination strategies and policy in South Africa are discussed.
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Abstract
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Developing and disseminating a preventive HIV vaccine is a primary scientific and public health
objective. However, little is known about HIV vaccine acceptability in the high prevalence setting
of South Africa—where young adults are likely to be targeted in early dissemination efforts. In 2007,
we conducted six focus groups (n=42) with South Africans aged 18-24 years old. We used a deductive
framework approach to identify key motivators and barriers to future HIV vaccine uptake.
Participants identified HIV testing, HIV stigma, mistrust of the health care system, and concerns
about sexual disinhibition as barriers to vaccine uptake. For women, family members and friends
were strong motivators for vaccine uptake, while men were more likely to see vaccines as an
opportunity to stop using HIV prevention strategies such as condoms and partner reductions.
Implications of these findings for developing HIV vaccine dissemination strategies and policy in
South Africa are discussed.
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INTRODUCTION
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South Africa carries one of the highest burdens of HIV globally. The overall HIV prevalence
rate for South African adults aged 15-49 is 18.8% and young women aged 25-29 have the
highest rates of infection in the country (Republic of South Africa: Department of Health,
2007; UNAIDS, 2006). Effective interventions to reduce the alarming rates of new HIVinfections among young South Africans are urgently needed. This includes directly engaging
communities and youth in the process of informing and developing appropriate and acceptable
HIV prevention strategies, including future HIV vaccines. Despite continued scientific
setbacks, many researchers, policy experts, and international institutions believe that a safe,
effective, and accessible preventive HIV vaccine represents the best long-term strategy for
controlling the HIV/AIDS pandemic (International AIDS Vaccine Initiative (IAVI) & The
Futures Group, 2005).
Research specific to post-trial HIV vaccine acceptability among high-risk populations around
the world is needed. Studies from South Africa suggest a wide variation of willingness to
participate in HIV vaccine trials, ranging from 23%-79% (Jaspan et al., 2006; Smit et al.,
2006). However, reasons for participating in vaccine clinical trials may be very different from
the factors influencing uptake of an approved HIV vaccine when it becomes available. For
example, altruism and desire to contribute to HIV research, commonly described as motivations
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for vaccine trial participation (Mills et al., 2004; Newman, Duan, Roberts et al., 2006), are
unlikely to play a significant role in decisions about uptake of an approved HIV vaccine.
Additionally, participants who volunteer for clinical trials are not representative of the wider
population that will be targeted with post-trial HIV vaccine dissemination efforts.
Considerably less is known about future HIV vaccine acceptability, and the few studies that
exist have been conducted in low prevalence settings of the US and Europe (Newman, Duan,
Roberts et al., 2006; Newman, Seiden, Roberts, Kakinami, & Duan, 2007). The stigma of HIV/
AIDS and mistrust of the health system and government have been described as barriers to
future HIV vaccine uptake in US and Europe, and we hypothesized they would be formidible
barriers to uptake in our study of South African youth. HIV/AIDS stigma has been reported as
a barrier to HIV testing (Daftary, Padayatchi, & Padilla, 2007; Macphail, Pettifor, Coates, &
Rees, 2006) as well as accessing and adhering to HIV treatment in South Africa and many
other countries around the world (Ncama et al., 2008; Weiser S, 2003).

NIH-PA Author Manuscript

Stigma may be further intensified by mistrust of health systems, science, and the government.
Mistrust of health systems and the reliability of HIV testing has been described in Uganda and
China (Dahl, Mellhammar, Bajunirwe, & Bjorkman, 2008; Wang et al., 2008), and mistrust of
the government and scientist in the context of failed large scale international trials have
influenced willingness to participate in trials of HIV vaccines and other biomedcial prevention
technologies (Bateman, 2005; Excler et al., 2008). Therefore, it is vital to conduct formative
research in Africa to ensure that future HIV vaccine availability will be translated into effective
dissemination strategies as well as clinical and public health benefits (Esparza et al., 2002;
SAAVI (South African AIDS Vaccine Initiative)).
In the present study, we explored future HIV vaccine acceptability among inner-city South
African youth, a high prevalence population likely to be targeted in early dissemination efforts.
The conceptual model (See Figure 1) for the present study is based on value-expectancy
theories and social marketing. The Theory of Reasoned Action (TRA) (Fishbein & Azjen,
1975), the Theory of Planned Behavior (TPB) (Ajzen, 1985), and the Health Belief Model
(HBM) (Becker & Joseph, 1988), are well-supported models that form the theoretical
underpinnings of social marketing. We employ components of each of these theories, i.e.,
vaccine attitudes (TRA &TPB), normative vaccine beliefs (TRA &TPB), and perceived risk
and severity of HIV (HBM), in order to systematically assess determinants of HIV vaccine
uptake. The Theory of Reasoned Action has been used widely to assess determinants of
intentions for hypothetical behavior, such as future condom use (Morrison, Gillmore, Baker,
& et al., 1995), as well as uptake of other vaccines (Schutten, de Wit, & van Steenbergen,
2002), and is similarly applicable to vaccine uptake after HIV vaccines become available.

NIH-PA Author Manuscript

METHODS
Sampling
We utilized a venue-based sampling strategy, as South African public sector clinics are likely
to represent the front lines of dissemination efforts once an HIV vaccine becomes available.
Our goal was to identify key barriers and motivators to future HIV vaccine uptake among a
population that interfaces with the health system and would be likely to be offered a vaccine
if it were available. The clinic serves a high-risk inner-city population characterized by poverty,
high levels of mobility, and large numbers of migrants from surrounding African countries,
particularly Zimbabwe. We purposively sampled young adults aged 18-24, as this is the age
group in South Africa when HIV incidence begins to sharply climb; thus young South Africans
would ideally be targeted in early dissemination efforts for a preventive HIV vaccine (Johnson,
Bekker, & Dorrington, 2007). Additionally, as the clinic services include STI screening and
treatment, TB services, reproductive health, and HIV counseling and testing, our sampling
Health Educ Behav. Author manuscript; available in PMC 2010 May 10.
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frame includes individuals who engage in HIV risk behaviors and would benefit from an HIV
vaccine.
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Participants
In early 2007, in collaboration with a local community clinic, we conducted two focus groups
with young men (n=7; n=10) and four with young women (n=6; n=6; n=6; n=7) seeking health
care at a public sector clinic in Johannesburg, South Africa. Participants were recruited by
fliers posted at the clinic and clinic staff who referred interested participants to the study staff.
Inclusion criteria for the study were: 1) aged 18-24 years; 2) ability to speak in one of two
African languages commonly spoken at the clinic; and 3) ability to provide informed consent.
Participants were compensated ZAR30.00 (approximately 6 US dollars at the time of data
collection) for their participation in the study. The University of the Witwatersrand Human
Research Ethics Committee and the Institutional Review Board of the University of California,
Los Angeles approved the study.
Data Collection
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We chose focus groups to explore future HIV vaccine acceptability, as this method facilitates
in depth discussion of individual perspectives within the context of a larger group, which in
turn may simulate peer group dynamics that influence decision-making outside of the study
setting (Kreuger, 2000). Focus group data was collected using a semi-structured discussion
guide (Table 1) that addressed key domains of the conceptual model, including: vaccine
knowledge, behavioral intentions to accept HIV vaccination, and barriers and motivators to
uptake of a future HIV vaccine (probing for attitudes, subjective norms, perceived control, and
perceived HIV risk). Participants were asked to discuss both their own opinions as well as their
perceptions of the opinions and attitudes of their peers. The fact that no effective HIV vaccine
currently exists, and no vaccine would be given as part of the study was stated in the informed
consent document, as well as at the beginning and at the conclusion of each focus group
discussion.

NIH-PA Author Manuscript

Focus groups were conducted in IsiZulu and SeTswana. The interview guide was developed
in English, and the focus group moderator reviewed the questions with study investigators in
order to determine correct terminology in IsiZulu and SeTswana. A separate study assistant
then translated discussion guide questions back into English, and any ambiguities or
inconsistencies were clarified. A South African woman fluent in IsiZulu, SeTswana (native
language) and English, assisted by a note taker, moderated the focus groups. Each group lasted
approximately 90 minutes. Written informed consent was performed at the start of the focus
group by the moderator. Participants completed a brief sociodemographic questionnaire at the
conclusion of the discussion. Socio-economic status was assessed by collecting information
on ownership of household durables ranging from basics such as piped water and electricity,
to mobile phones and refrigerators, to luxuries such as satellite TV and domestic workers.
Participants received one point for each of the 20 items, and the range and mean score of
durables was calculated.
Data Analysis
Discussions were audiotaped with participants’ permission and tapes were independently
translated and transcribed in a single step. This single step approach was taken as the
discussions involved words and passages in all three languages (IsiZulu, SeTswana and
English), and did not have fidelity to one language alone. The multilingual focus group
moderator as well as two of the English speaking investigators checked each individual
transcript for accuracy. When inconsistencies or questions arose, the passage was transcribed
first into IsiZulu or SeTswana, and then translated into English, followed by independent back
translation to resolve inaccuracies. During the transcription/translation process a participant
Health Educ Behav. Author manuscript; available in PMC 2010 May 10.
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code was assigned to each text passage in the focus group transcript, so that each statement
may be identified at the participant and the group level. Two principal investigators (JS and
CM) read the transcripts to identify major themes. Next, the investigators independently
performed a line-by-line review of the transcripts and hand coded for each major theme using
a framework analysis approach (Pope, Ziebland, & Mays, 2000). Text corresponding to each
of the themes was grouped together and reviewed. Inter-coder reliability was assessed for a
random 10% of the text, and the Kappa statistic was calculated to be 0.90.
Analysis continued as an iterative process through discussions and refining of the major themes.
Sub-themes were then established using a method of constant comparison (Strauss & Corbin,
1998) to break down higher-level codes (themes) into smaller categories or sub-themes within
the framework. Data source triangulation (comparing data across focus groups as well as
between male and female groups), as well as collaboration (patients and staff from clinic
provided input on wording and orientation of study questions as well as feedback on themes
found in interpretive analysis), researcher reflexivity (interpretive commentary considers
researchers lens/point of view), and rich description was used to enhance the validity and
reliability of the findings (Creswell & Miller, 2000).

RESULTS
NIH-PA Author Manuscript

Background characteristics
Sociodemographic characteristics of the participants are presented in Table 2. The mean age
of participants was 21.5 years, with the majority being involved in full-time study (43%); 30%
of the overall sample reported some or no high school education. Of 20 potential durables, the
maximum was 19, the minimum 0 and the mean 9. Ownership of household durables ranged
from 85% (electricity) to 5% (domestic worker in the home). The vast majority of participants
were not married (95%); just over half reported a single sexual partner in the past 3 months
and almost two-thirds of these reported using a condom at last intercourse. Two-thirds reported
having previously had an HIV test.
Knowledge About Vaccines—General knowledge about vaccines was relatively low,
particularly for young women who did not have children, and young men.
To be honest I don't know anything [about vaccines] but I think I know what they
do... it boosts your immune system and it helps you live longer (Male participant).
Initial discussions about vaccines were introduced within the context of routine childhood and
adult vaccinations. About half of female participants, and very few male participants were
familiar with childhood vaccines. One participant explains:

NIH-PA Author Manuscript

When they take (babies) to the clinic to inject them, it is for the children not to be
affected by any diseases when they are still young. It is for their survival while they
are still young (Female participant).
The most commonly recognized childhood vaccines were polio and measles (mentioned in 5
of the 6 groups), although whooping cough and tetanus were also mentioned in 2 groups. The
three female participants with children had the highest knowledge of childhood vaccines.
Knowledge about adult vaccinations was limited. A small number of participants had
experience with flu vaccines, and others had heard of recent developments in vaccines for
prevention of sexually transmitted disease (the HPV vaccine had been recently approved and
was in the news at the time of the study). Participants familiar with vaccines were also aware
of attributes, such as the need for repeat dosage (or boosters) and minor side effects that may
occur immediately after vaccination. One participant explained his understanding of vaccines:

Health Educ Behav. Author manuscript; available in PMC 2010 May 10.
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Vaccines I would say are anti body precautions medicines, like you are given maybe
anti body of a certain virus in order to make sure that the day you get that virus, it can
be battled, like for example... in order to prevent flu you are... injected with anti bodies
for flu. (Male participant)
In five of the six focus groups, there was a need for clarification of the role of vaccines as
prevention as opposed to treatment. Additionally, participants were curious as to what made
some HIV prevention methods vaccines and others not. For example, several participants asked
about whether condoms, antiretroviral medication to prevent mother-to-child transmission and
microbicides could be considered HIV vaccines. “I think a condom is one of the HIV/AIDS
vaccines to prevent people from getting HIV” (Female participant). Interestingly, at least one
participant in three of the six focus groups was aware that HIV vaccines were being developed
and tested. The majority of participants were not aware of efforts to develop HIV vaccines in
the international community. None of the participants thought that an HIV vaccine was
available currently.
They are not on the market; they are still discussing the issue. The government,
Mantwa [Minister of Health] and everyone you know. Some are saying it is good,
some are saying it is bad.’(Female participant)

NIH-PA Author Manuscript

Barriers To Future HIV Vaccine Uptake—Overall, vaccine acceptability was high among
participants in both male and female groups. Approximately three-quarters of participants
reported that if an approved HIV vaccine was available, they and their friends/family would
take it. However, important barriers to uptake of the vaccine were also identified.
Mistrust of government and scientists: Participants in all of the 6 focus groups brought up
concerns about receiving reliable and trustworthy information about an HIV vaccine once it is
available. Mistrust of the government and the scientific community was reflected in a belief
that the risks or toxicities associated with an HIV vaccine would not be fully disclosed to the
public. One participant explains, “We must also be careful if they [government] are trying to
make people sick...They just introduce something to the market and don't tell us anything about
it and then after that people die from that thing.” (Female participant)
Similarly, participants in each of the six groups expressed concern that the public may be misled
into thinking that an HIV vaccine provides a higher level of protection than it actually does.
People may not get the vaccine because they are not trusting...you might find that
[scientists] are saying the vaccine does work, and then you get the vaccine and it
doesn't help you. People think, “they are just pulling our socks again”...because they
have told stories like this before. (female participant)

NIH-PA Author Manuscript

In this context of mistrust, vaccine efficacy demonstrated by researchers with carefully
designed clinical trials was not reliable evidence to participants. The majority of participants
who expressed mistrust believed that the most accurate information about the effectiveness of
a vaccine comes from the personal experiences of friends, family, and other community
members. One example was knowing someone firsthand who got the vaccine, then had an HIV
exposure through unprotected sex with a person who was known to be HIV-infected, and did
not contract the virus. “I would want to see with my own eyes if this person is getting sick or
not, then I would use it. In the papers they would tell you that today it's working, tomorrow it's
not...So if I see that it is working for my friend, then I would use it also...” (Male participant)
Associations of vaccine uptake with stereotypes of promiscuity: Another potential barrier
to HIV vaccine uptake was fear of being labeled sexually promiscuous because of taking the
vaccine. Nearly all participants described how partners, parents, family, church members, and
the community overall might question why a young person would “need” an HIV vaccine,
Health Educ Behav. Author manuscript; available in PMC 2010 May 10.
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equating its use with admission of sexual activity or having multiple partners. For example,
one young man says, “If I tell my girlfriend I'm going for a HIV vaccine...She'll go: Why do
you need it? You only have me.” Female participants also frequently expressed concerns about
being labeled ‘promiscuous’ or a ‘prostitute’ by parents, family members, or the church if they
were to take an HIV vaccine. “In my family I would be considered an outcast if I take it...they
follow the church teachings without hesitation, and they will call me a prostitute for not using
my own behavior alone to prevent AIDS.” (Female participant)
While concerns about the reactions of family and the church were not raised in the male focus
groups, several young men described possible stigmatization within the community or medical
care setting. One participant said “This guy is going for the HIV vaccine, so he's accusing
himself...they are associating it with someone who's been sleeping around...like he has bad
behavior. I think one of the reasons he won't get [the vaccine] will be this stigma.” Interestingly,
even though HIV is overwhelmingly an epidemic of heterosexual women and men in South
Africa, one male participant described concerns about stereotypes of homosexuality, “Some
would believe that you are gay, you need vaccines for gays.”

NIH-PA Author Manuscript

Fear of HIV testing and HIV stigma as barriers to vaccine uptake: Two of the most
commonly mentioned barriers to HIV vaccine uptake were fear of having to test for HIV prior
to receiving a vaccine, and fear of the stigma that one would encounter if she/he were HIVpositive. Participants in 5 of the 6 focus groups described how a requirement to be tested for
HIV prior to being given the vaccine would result in many people forgoing vaccination. One
female participant says, “We won't use the vaccine. It's the same as now, I hear that treatment
for HIV is for free, but I don't know my status. So it's the same [with] taking the vaccine.” A
male participant described how the emotional toll of HIV testing may be a barrier to vaccine
uptake, “While I'm waiting for my [HIV test] results there's too much stress, so I will have too
much stress and I will end up having depression...I won't agree to go to the clinic first and test.”
Uptake of the HIV vaccine was also described as a way of revealing a person's HIV status, as
most participants believed that only HIV-negative persons would be offered a preventive
vaccine. Therefore, knowing if a person received the vaccine would also disclose their HIV
status and lead to potential stigma and discrimination for those who are HIV-positive. As one
male participant describes, “The vaccine will be for negative people, so if you go and get the
vaccine, we know you are negative...[I]f this guy didn't go, he's positive and that's why...so
that is the stigma for HIV-positive people.” In 4 of the 6 groups participants report that because
of low levels of knowledge about vaccines in the community, people who take the vaccine may
end up being labeled as HIV-positive and stigmatized:

NIH-PA Author Manuscript

People will be afraid of rumors because not everyone is educated. People will think
that if they take the vaccine others will think they have HIV...The community will
stay away from you if they know you took the vaccine...I think they will confuse this
vaccine with ARVs [antiretrovirals]. They will think if you take the vaccine it means
you are HIV-positive. (Female participant)
Regardless of the direction of the stigma (i.e. for those who take vaccine or those who do not)
participants agreed that it could influence decisions about vaccine uptake, “People won't get
the vaccine because they are going to be ashamed...they will think they look suspicious when
they go to get it...” (Female participant)
Vaccine Characteristics as Barriers to HIV Vaccine Uptake: The potential for side effects
was also described as a barrier to future HIV vaccine uptake. Participants were familiar with
side effects of childhood vaccines, and one or two in each group had also experienced side
effects such as fevers, chills, and general malaise from receiving the influenza vaccine as an
adult. One female participant explained:
Health Educ Behav. Author manuscript; available in PMC 2010 May 10.
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Last year I had a flu vaccine because I was scared that the flu was gonna come very
hectic on me...I became so sick from that vaccine! So I got sick because I was trying
to prevent that disease...Since that time I told myself, no I'm not gonna do any vaccine
no more.
Another participant shared this perspective, indicating that she preferred nutrition as an
alternative to vaccines for disease prevention, “I think vaccines are going to make people sick.
People must just eat healthy food to prevent everything.”
Participants also discussed duration of protection as a vaccine characteristic that may affect
uptake. Interestingly, nearly all participants said they would prefer a duration of protection of
a year or shorter, citing more frequent administrations or boosters as a way of knowing the
vaccine is “active” in their body. Many participants believed they would distrust the efficacy
of a vaccine that was only administered once or infrequently, “If it's once in my whole life I
wouldn't trust it.” (Female participant)

NIH-PA Author Manuscript

Cost was another potential barrier to vaccine uptake. There was consensus that a high cost
vaccine would clearly be a barrier for much of the population, particularly among the young
and those unemployed or living on government grants. However, several participants pointed
out that a free vaccine might also have poor uptake, particularly among youth. Participants
describe a perception among themselves and their peers that free items are inferior to those
that come at some cost. One male participant described his opinions about HIV vaccine
acceptability and cost:
So if we get that vaccine...if it will be for a thousand rand, people will know and it
will motivate them. If it's for free, everyone takes it for granted that he knows that
anytime I'm going to get that. But if they know that it's their money they have to work
for, sweat for it and then they go to buy the vaccine...that kind of value people will
take it serious.
Lack of perceived vulnerability: There was a wide range of perceived vulnerability to HIVinfection in our sample of South African youth. About a quarter of participants in each group
expressed concern about contracting HIV themselves and the impact of HIV on the greater
community. In the words of one young man, “this disease is killing us, it's killing our society.”
However, in five of the six groups, other participants felt they were not personally vulnerable
to HIV and didn't need the vaccine because they did not engage in risky sexual behavior, or
they used condoms regularly. One female participant explained, “You can perceive me the way
you want to, I'm sorry, I won't get it [vaccine]. I haven't had sex without a condom and I will
never ever.”

NIH-PA Author Manuscript

Perceived vulnerability to HIV was also described as varying between urban and rural
communities. In four of the six groups participants believed that rural communities were less
likely to think that they were at risk for HIV, which may become a barrier to vaccine uptake.
One participant explains, “People who live in those [rural] parts, they take AIDS as if it's
something that is in Jo'burg only...they don't take it as if in Venda [rural tribal area] there is
AIDS and HIV, they don't even take it seriously.”
Community attitudes about HIV: Community attitudes and blame for HIV were described
as influencing vaccine uptake in each of the six groups. For example, one participant explained
how in his own community the older generations blame the young for behavior that introduced
the disease of HIV. Furthermore, he describes how a belief that HIV vaccine will promote
promiscuity in youth may be a barrier for parents.
For us in the black community everything is a problem. Like parents believe that HIVinfection comes through children, they themselves don't know it because in their days
Health Educ Behav. Author manuscript; available in PMC 2010 May 10.
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when they begot children there was not things like HIV...They believe the youth
brought AIDS, so when there's a vaccine, they gonna think it's another plan to make
children more sexually active...they won't accept it.
Participants also described the role of religion in shaping attitudes about HIV vaccines. One
young woman describes how religious beliefs and fatalism may interfere with HIV prevention
and vaccines specifically:
People who say they are Christians can say no to that vaccine thing ‘cause in the Bible
it's stated that there's this disease that is going to kill people and it can never be
prevented...it's gonna stay here, it's going to kill people because it [the Bible] says the
world is coming to an end...
Another male participant articulated the need to resist social norms and community beliefs that
may be barriers to vaccine uptake, “I want to challenge the moral thing, people should have a
chance to really get to discuss, and then go home and think about it, and how am I gonna take
the next step? Am I going for the vaccine or not? ‘Cause there will be social conditionings,
there will be gender conditionings, if as an individual you still base your thoughts on other
people...”

NIH-PA Author Manuscript

Traditional African healing: In two of the six focus groups, participants discussed how beliefs
in traditional African healing may deter individuals from an HIV vaccine. The vaccine was
categorized as a “western medicine,” and was not viewed to be compatible with the traditional
African healing paradigm by some participants. Those who had experience with traditional
healers expressed skepticism and mistrust of western medicine, “We have to stick to our
tradition...our culture, our socialization ‘cause if I was taught not to get pills because pills are
associated to bombs, or to wherever they are manufactured...it would not be easy to accept the
vaccine.”
Motivators Of HIV Vaccine Uptake
Protection against HIV transmission risks outside of one's control: The most frequently
discussed motivator for HIV vaccine uptake was the ability to be protected from HIV when
the transmission risk was out of an individual's control. Over half of the participants perceived
non-sexual modes of HIV transmission to be a significant threat, including injuries from car
accidents, sewing needles, nail cutters, and injections received at the hospital. For example one
female participant asked, “What if you use a condom and get HIV in a car accident? Why don't
you just take the prevention [vaccine] and be safe forever if you are negative?” Some believed
that non-sexual HIV transmission was their only risk of contracting HIV, “I will use it for safety
in car accidents, not in sex.”

NIH-PA Author Manuscript

Sexual modes of transmission that were out of an individuals control, such as partner infidelity
and rape, were also described as strong motivators for using an HIV vaccine in all six groups.
One woman explained, “If I have taken that [vaccine] ...if my partner cheats on me I will be
able to have prevention.” Similar benefits of being vaccinated, specifically in the context of
marriage were also discussed, “One day I would like to get married, I don't know what my
husband will be like, so I'm just preventing myself from getting the disease...I know I can trust
him, but maybe things will change and I won't.” A young man expressed the benefits of a
vaccine for men in the context of rape in prisons:
For me, in a prison scenario...you might get raped and get HIV, so having the vaccine
available there is a great place to start. It should become a protocol in prison, after
you get your prison number you get a vaccine, ‘cause they don't know whose gonna
rape you in there...so at least your chance of getting HIV is less.”

Health Educ Behav. Author manuscript; available in PMC 2010 May 10.
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Desire to raise a family: Female participants described the desire to live to parent their child,
as well as the ability to have a family with an HIV-positive partner as two important reasons
they would consider taking an HIV vaccine. With regard to parenting one woman said, “I am
a parent myself...and here is the vaccine, it's available, and I think I would use it just for me to
raise my child.” Another participant explained the role an HIV vaccine could play in allowing
her to start a family with an HIV-positive partner. “I support the vaccine because if I'm not
married and I meet someone who is HIV-positive, and I'm negative ...if I love that person and
I want to have a baby...it is better to go and get the vaccine.”
Unprotected sex and multiple partners: Whereas women described the desire to raise a
family as a central motivator of vaccine use, the majority of men cited the ability to have sex
without a condom and having multiple sexual partners as advantages of taking the HIV vaccine.
Several men in each group stated that if a vaccine were available they would not need to worry
about HIV prevention, and therefore would not need to use a condom or limit the number of
sexual partners they had. In the words of one male participant, “with the vaccine...one
advantage is people would enjoy sex without condoms, because now many do not enjoy with
a condom.” Another stated “I won't have stress about HIV anymore, I can just go for it like
nobody's business...”

NIH-PA Author Manuscript

Male participants also described advantages of the vaccine in the context of a primary
relationship: “If the HIV vaccine becomes available, you can have more than one partner... [B]
ut if there's a partner that you would want to spend the rest of your life with, you can secretly
cheat as long as HIV is not there.” It is important to mention that four of the men in the focus
groups reacted strongly to the discussion about increased promiscuity, stating their sexual
behavior would not change significantly if a vaccine was available. However, all male
participants were in agreement that these factors would be seen as a motivator for vaccine
uptake among many of their peers.
Among female participants, reduced condom use and multiple sexual partners in the setting of
a HIV vaccine was described as a concern as opposed to a motivator. Several women in each
group felt that decreased condom use would not be an advantage of the vaccine because it
didn't protect against pregnancy and other STDs. In addition, several female participants
expressed concern that fidelity and “moral” sexual behavior would be compromised by an
effective vaccine, “If a vaccine is available people will not fear HIV anymore. Now the fear
of HIV keeps people's moral behavior under control.”
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Community, government, and media: Individual communities, the government, and the
media were all described as having the potential to improve vaccine uptake through education,
influencing social norms, and providing incentives to use HIV vaccines. In describing his
community's attitude toward an HIV vaccine, one man said, “Discrimination will end. People
would just say its better to do this [vaccine] because they are parents themselves. In their
community they see people related to them [get sick], they also lose people, so they would just
say it's a go!” Another participant described the importance of considering social inequities in
society when addressing HIV prevention and vaccine use:
If we say why is this virus spreading a lot I would code issues of poverty, war, conflict,
violence...rape...refugee camps...sex work because there are no jobs. As much as we
want the vaccine we need to see other ways of improving it [prevention], like reducing
unemployment and attacking those problems.
Participants also believed the government could play a significant role in improving HIV
vaccine uptake through the use of incentives, mandates, and outreach. One male participant
suggested, “Those who come for injections, maybe they will give one hundred [Rand/ZAR;
$20 USD] for groceries to each...they [government] should give them incentives so they can
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be vaccinated.” Another female participant believed that the vaccine should be mandated, “If
this vaccine was to be available, I would personally suggest to the government that everybody
should be injected.” Participants also believed vaccine dissemination and uptake could be
enhanced by outreach to rural and high risk communities, “Access to mobile visiting cars to
get it [vaccine]...outreach to rural areas, supermarkets...even the bar with sex workers, so before
you buy [sex] at least there is someone who has the vaccine” (male participant).
In all six groups the media was cited as another important facilitator of vaccine uptake, both
through education and community mobilization. One female participant explained:
I think it is different in rural areas, some people don't have that knowledge so...I think
the government should do a drama ...like Generations [a soap opera]...so at least
people have enough knowledge to know [the vaccine] is saving lives.
The role of the media in mobilizing the community through newspapers, TV, radio, billboards
and advertising was also emphasized. One male participant describes the importance of a
collaborative approach, “ Like we did with HIV when people didn't actually believe it is here
and killing people...the government went in, and the youth went in, the media, everybody went
in...so that is how we have to do it...we must show people that here is someone who does not
have AIDS who took it [vaccine]...and slept with somebody who had AIDS but he didn't get
infected.”
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DISCUSSION
Few studies have examined future HIV vaccine acceptability in the setting of high prevalence
African countries. In this study, we use a conceptual model grounded in value expectancy
theory and social marketing to study the behavioral intentions of young adults in South Africa
with regard to acceptability of a future HIV vaccine, and barriers and motivators to future HIV
vaccine uptake. Aspects of our conceptual model that were particularly relevant to the study
sample were the role of behavioral and normative beliefs, social norms, and perceived risk as
barriers and motivators to future HIV vaccine uptake. We found these beliefs, norms and
perceptions to be most powerful in shaping the acceptability of a future HIV vaccine in our
sample, relative to the more tangible hypothetical vaccine characteristics. Knowledge of
vaccines in general and HIV vaccines specifically was low in the sample, and our model
suggests utility in efforts to improve knowledge about HIV prevention overall, including
testing, behavioral change, and vaccines when developing dissemination plans for a future HIV
vaccine.
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While our participants differ in many ways from the US populations that have been previously
studied, we found several barriers to HIV vaccine uptake common to both groups, suggesting
these factors may be important in the context of both the developed and developing world.
These included fear of side effects, high cost, HIV stigma and discrimination, as well as mistrust
of health care professionals and government as barriers to vaccine uptake (Newman et al.,
2006; Rudy et al., 2005). Similar to the findings of Rudy et al., our participants also identified
a role for the health care system and government to promote positive subjective norms that
encourage HIV vaccination for the public.
One newly identified and commonly mentioned barrier to HIV uptake in our sample of South
African young adults was HIV testing in the setting of vaccination. Fear of HIV testing was
frequently mentioned in both female and male groups, and many participants believed that a
requirement for testing prior to receiving vaccination would be a barrier to dissemination
efforts. Fear of HIV stigma and discrimination continues to discourage testing among South
African youth, despite free access to HIV treatment (Macphail et al., 2006). Participants in
clinical trials of vaccines have also expressed concerns about having to first learn of their HIV

Health Educ Behav. Author manuscript; available in PMC 2010 May 10.

Sayles et al.

Page 11

NIH-PA Author Manuscript

status before enrolling in trials (Smit et al., 2006). Attitudes about HIV testing, fueled by the
pervasive stigma of HIV, have the potential to hinder dissemination efforts. There will be a
continuing need to study and address these issues in order to optimize uptake of a future posttrial HIV vaccine in contexts such as South Africa where fear of stigma and discrimination are
widespread barriers to testing.
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We found that knowledge about vaccines generally, and HIV vaccines specifically, were low
for the majority of participants, with the exception of those who were parents or caretakers and
had experience vaccinating a child. This is despite a publicized HIV vaccine trial in a
neighboring community in Johannesburg that was ongoing during the study period. Our
findings are consistent with research from the KwaZulu-Natal region of South Africa, which
reported that 48% of participants had never heard of HIV vaccines (Lindegger, Quayle, &
Ndlovu, 2007). This is in contrast to the levels of knowledge in communities in Uganda, where
good access to childhood immunization programs is thought to contribute to knowledge and
familiarity with vaccines (Kiwanuka et al., 2004). Confusion about the role of vaccines as
preventive agents rather than treatment, and the mechanism of action that delineates vaccines
from other types of prevention (microbicides, condoms) was also present in our sample, and
has been previously documented in South African populations (Lindegger et al., 2007) as well
as among military conscripts in Uganda (McGrath et al., 2001). Our results suggest that
education about vaccines in general, and the specific protection provided by HIV vaccines will
be an important component of community preparedness efforts in populations that do not have
high penetration of childhood or other adult vaccines.
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Mistrust of information about an HIV vaccine provided by the government, scientists, or the
media was another potential barrier to vaccine uptake, which has been described in ethnic
minority and low socioeconomic US populations (Newman et al., 2006; Roberts, Newman,
Duan, & Rudy, 2005). In our study, this mistrust arose in the context of recent highly publicized
South African microbicide trials that may have put trial participants at increased risk of
contracting HIV, and a government that many felt was slow to act to stem the HIV epidemic,
denied that the HIV virus caused AIDS, and whose Minister of Health has consistently endorsed
nutritional supplements over antiretroviral therapy for the treatment of AIDS. While mistrust
may be intensified by the specific political economy of South Africa, previous studies suggest
that the lack of transparency and false information that has fostered mistrust of the government,
science, and health care are not unique to South Africa (Newman et al., 2006; Roberts et al.,
2005), and have the potential to interfere with dissemination efforts around the world. A smaller
number of participants also felt that mistrust of western medicine and a preference for
traditional African remedies may also limit uptake of an HIV vaccine. The practices of
traditional medicine and “western” medicine were largely viewed as mutually exclusive,
reflecting contrasting illness paradigms. Our findings suggest a great need for discussion and
collaboration between traditional practitioners and “western medicine” if biomedical HIV
prevention efforts are to be successful in countries where both types of practice are prevalent.
Overall, motivators for vaccination differed by gender. Women's discussions tended to focus
on the normative beliefs of family members and friends as strong motivators for vaccine uptake,
while men were more likely to see vaccines as an opportunity to stop using HIV prevention
strategies such as condoms and partner reductions. The potential for sexual disinhibition in the
context of an approved HIV vaccine is suggested by our findings; however, women were
primarily concerned about disinhibition among men rather than changes in their own behavior.
This suggests that education and risk reduction counseling for other sexually transmitted
infections and pregnancy are likely to be critical components of any post-trial HIV vaccine
dissemination campaign and that interventions may need to be tailored by gender.
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We chose the focus group method to explore acceptability of a future HIV vaccine. The
limitations of focus groups include overrepresentation of specific participant contributions, as
certain individuals may dominate the conversation or influence the overall dynamics in the
group (Kreuger, 2000). However, we did take steps in coding to track and account for comments
at the individual participant level. While we did not engage participants in formal member
checking, our study included several methods for improving validity of qualitative studies,
including triangulation, collaboration, researcher reflexivity, and rich description. Because the
focus groups included mixed IsiZulu, SeTswana, and English words/passages, we used a
modified translation protocol that did not involve transcribing all text into one African
language, followed by translation and back translation. This means there may have been errors
in translation/interpretation that were not identified by the investigators. We chose to
purposively sample participants from an inner city clinic serving large numbers of patients
with sexually transmitted infections, as it allows us to identify key barriers to vaccine uptake
among young women and men who are engaging in HIV risk behaviors and would most benefit
from an HIV vaccine. However, our goal was not to recruit a representative sample, thus our
results may not generalize to all South African youth. Because participants were already
seeking medical care, our sample may be biased toward participants who view biomedical
prevention more favorably than those recruited from other venues, for whom HIV vaccine
acceptability may be more challenging. Additionally, the majority of our participants have had
at least some high school education, and results may differ among youth with lower levels of
education and literacy. Despite these limitations, we were able gain important new knowledge
about key factors that may influence behavioral intentions to accept an HIV vaccine, once it
becomes available. Future studies that include representative samples in areas with high HIV
prevalence, and examine the role of HIV vaccines on sexual risk behavior are needed to prepare
for future post-trial dissemination campaigns.
Implications for Practice
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This study identifies a range of perceived barriers and motivators to uptake of a future HIV
vaccine, including mistrust of the government and scientific community, HIV/AIDS stigma,
as well as concerns about cost and equitable distribution. These barriers mirror many of the
challenges faced by practitioners in behavioral HIV prevention efforts, HIV testing, and HIV
treatment in many parts of the world, and may play a role in fueling the existing health
disparities for persons living with HIV/AIDS (Newman, Williams, Massaquoi, Brown, &
Logie, 2008; Tsai, Chopra, Pronyk, & Martinson, 2008). Partnerships between practitioners
and communities to improve rates and acceptance of HIV testing as well as sustained efforts
to destigmatize HIV/AIDS are of critical importance to effectively address disparities in HIV/
AIDS today, and to prevent further disparities in future HIV vaccine dissemination efforts. In
our study, participants articulated the need to challenge moralistic and polarizing views of HIV
in order to facilitate open discussion and enable individuals to make informed decisions about
future HIV vaccine uptake. In this context, a discussion of biomedical prevention may provide
the health educator opportunities to reframe HIV risk and prevention, and to move beyond
moral codes of behavior. Discussions of biomedical prevention also may serve as a vehicle to
encourage community dialogue between younger and older generations that address stigma
and social norms, which are impediments to the success of existing HIV prevention and
treatment.
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Figure 1.

Conceptual Model for Future HIV Vaccine Acceptability
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Table 1

Focus Group Discussion Guide
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Focus Group Discussion Questions
KNOWLEDGE OF VACCINES
What is a vaccine?
What vaccines have you heard about or are you familiar with?
What do you know about vaccines or about how they work?
KNOWLEDGE OF HIV VACCINES
What have you heard about vaccines for HIV/AIDS?
BEHAVIORAL INTENTIONS
Would you or your close friends be willing to be vaccinated against HIV/AIDS? Why?
MOTIVATORS: ATTITUDES, SUBJECTIVE NORM, PERCIEVED CONTROL / RISK
What would be the reasons you or your close friends would want to be vaccinated against HIV/AIDS?
BARRIERS: ATTITUDES, SUBJECTIVE NORMS, PERCIEVED CONTROL / RISK
What are possible concerns or barriers to you or your friends’ taking an HIV/AIDS vaccine?
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VACCINE CHARACTERISTICS
Are there certain characteristics of a vaccine that you think are important or might influence whether you take it?
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Table 2

Sociodemographic Characteristics of Focus Group Participants
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Characteristics

% Sample (n)

Age (n=42)
18-22

64.3 (27)

23-26

35.7(15)

Gender (n=42)
Male

40.5 (17)

Female

59.5 (25)

Main Occupation (n=41)
Full time student

41.5 (17)

Part time student

7.3 (3)

Employed

34.1 (14)

Unemployed / not student

17.1 (7)

Education (n=40)
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No / some high school

30.0 (12)

Completed high school

30.0 (12)

Some tertiary studies but no graduation

40.0 (16)

Marital Status (n=42)
Single

95.2 (40)

Married

2.4 (1)

Separated

2.4 (1)

Ethnic Group (n=40)
Ndebele

20.0 (8)

Zulu

27.5 (11)

Tswana

10.0 (4)

Tshivenda

17.5 (7)

Other ethnic group

25.0 (10)

Partner in the last 3 months (n=41)
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None

31.7 (13)

One

51.2 (21)

Two

12.2 (5)

Three or more

4.9 (2)

Condom use last time had sex (n=36)
Yes

63.8 (23)

No

36.1 (13)

Had HIV test (n=42)
Yes

61.9 (26)

No

38.1 (16)

HIV Status (n=41)
HIV +

7.3 (3)

HIV –

53.7 (22)
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Characteristics

% Sample (n)

Don't know

39.0 (16)
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